Study of B007 for Generalized Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with generalized myasthenia gravis (not the mild eye-only type or very severe crisis)
- Positive for AChR or MUSK antibodies in your blood
- Moderate to severe symptoms: your MG-ADL score (a daily activity rating) is 5 or higher
- On a stable dose of your usual myasthenia gravis treatments (like steroids or immunosuppressants)
- Willing to use effective birth control during the study and for 1 year after the last drug dose (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
This trial tests a new drug called HN2301 for patients with generalized myasthenia gravis (a disease where the immune system weakens muscles) who have not responded well to standard treatments. The goal is to see if HN2301 can safely improve muscle strength and daily function.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.